Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cardiopulmonary Bypass–associated Acute Kidney Injury

Open access
Kumar, Avinash B., Suneja, Manish, Riou, Bruno·2011·Anesthesiology

Abstract

APPROXIMATELY 300,000 patients undergo cardiac surgical procedures each year in the United States. More than 80% of routine cardiac surgical procedures are performed using cardiopulmonary bypass (CPB).1Acute kidney injury (AKI; previously referred to as acute renal failure) after CPB is a well-known, yet incompletely understood, entity that has significant implications on both short- and long-term outcomes. The development of AKI after CPB is associated with a significant increase in infectious complications, an increase in length of hospital stay, and greater mortality when compared with patients without AKI-CPB.2The incidence of AKI-CPB averages 20–30%, depending on the definition used and the duration of the postoperative period studied.3,4Furthermore, more patients with AKI-CPB who require dialysis remain dialysis dependant. For all patients undergoing CPB, the risk of AKI-CPB is the least in those who undergo coronary artery bypass grafting (CABG) only; the risk increases for patients undergoing valve replacement surgery; and the risk is the greatest after combined CABG-valve procedures.4There has not been a significant reduction in mortality, despite many recent advances in our understanding of the causative pathophysiology and pharmacotherapeutics of AKI-CPB. Furthermore, advances in renal replacement therapies (RRTs) have not significantly altered the overall mortality associated with AKI-CPB.In this review, we will focus on the current definitions of AKI, pathophysiologic features, and risk factors for developing AKI-CPB. We will also discuss perioperative strategies and emerging concepts that add to our understanding of this complex entity to help better manage patients at risk for AKI-CPB.AKI is a complex diagnosis and has been described using several definitions and diagnostic criteria, ranging from a 25% increase in baseline serum creatinine (sCr) to the need for hemodialysis.3,4The requirement for a consensus definition addressing early detection and grading of severity of AKI led to the development of the Risk-Injury-Failure-Loss-End stage kidney disease (RIFLE) classification by the Acute Dialysis Quality Initiative.5To further refine the scoring, the Acute Kidney Injury Network (AKIN) proposed a modification of the RIFLE classification, known as the AKIN classification.6The RIFLE and AKIN classifications have been used and validated in prospective studies7in patients with AKI after cardiac surgery.The differences between RIFLE and AKIN staging criteria are subtle. Stage 1 in the AKIN classification has been broadened to include patients with an increase in sCr of at least 26.5 μM (0.3 mg/dl) greater than baseline because there is accumulating evidence that even minor increments in sCr concentration are associated with adverse outcomes.6In contrast, the “risk” stage of RIFLE classification requires a 50% increase in sCr over baseline. Urine output over time is retained in both classification systems because it may precede the increase in sCr, especially in critically ill patients. The AKIN classification uses a 48-h window for assessment of renal function, whereas the RIFLE classification uses a 7-day window. The time constraint of 48 h was selected by AKIN based on evidence that adverse outcomes were reported when the creatinine elevation occurred within 24–48 h of hospitalization.6Any patient treated with RRT, irrespective of urine output or sCr concentration, is categorized as having a stage 3 condition in the AKIN system. In contrast, the RIFLE system classifies patients receiving RRT under the “loss” or “ESKD” (end stage kidney disease) group, depending on the duration of RRT. The loss and ESKD classes are removed from the AKIN classification because they represent outcomes or long-term phases of the disease process, rather than the short-term processes.Both classifications have limitations. Neither indicates the actual site of kidney injury (e.g. , tubular or glomerular injury). In addition, both classifications rely heavily on sCr, which, by itself, is not an ideal biomarker for AKI. In general, there is no clear consensus regarding the advantage of RIFLE versus AKIN for patients with AKI-CPB.7The diagnostic criteria for both systems are outlined in table 1.The pathophysiologic features of AKI-CPB are complex and multifactorial. Reduced renal perfusion pressure, activation of proinflammatory mediators, and direct nephrotoxicity are central in the pathogenesis of AKI-CPB.8CPB itself contributes to the pathogenesis via the systemic inflammatory response syndrome, sequelae of alterations in regional blood flow and vasomotor tone in the kidneys, and the generation of microemboli. CPB-associated systemic inflammatory response syndrome is triggered primarily by the contact of blood components with the artificial surface of the bypass circuit. Tumor necrosis factor α, interleukin (IL) 6, and IL-8 are key cytokines implicated in the pathogenesis of AKI-CPB, but their precise role is not clear

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aln.0b013e318210f86a

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 199

Metadata

Authors
Kumar, A. B., Suneja, M., & Riou, B.
Venue
Anesthesiology
Published
2011-04-01
Volume
114
Issue
4
Pages
964-970
ISSN
0003-3022 (ISSN-L)
OpenAlex
W2013873227
Cited by
199
References
2
FWCI
7.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiopulmonary Bypass–associated Acute Kidney Injury. https://app.cochat.ai/papers/10.1097/aln.0b013e318210f86a
The paper
Kumar, A. B., Suneja, M., & Riou, B. (2011). Cardiopulmonary Bypass–associated Acute Kidney Injury. Anesthesiology. https://doi.org/10.1097/aln.0b013e318210f86a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.